# MIST catalysts: Milestone Pharmaceuticals Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mist/catalysts

> Milestone Pharmaceuticals Inc. (MIST) has 2 upcoming catalysts. The next is the CARDAMYST (etripamil) trial start, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MIST?

Milestone Pharmaceuticals Inc. (MIST) has 2 upcoming catalysts. The next is the CARDAMYST (etripamil) trial start, 2H 2027. Press release filed with the SEC (EX-99): "Company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above." [Calendar and source filings](https://sec-api.dev/companies/mist/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-059780, https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-05-13. Cite: https://sec-api.dev/companies/mist/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Milestone Pharmaceuticals Inc. |
| Ticker | MIST (Nasdaq) |
| SEC CIK | 1408443 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mist |

## Cash runway

Cash $145.4M as of 2026-09-30; quarterly burn $25.2M; about 17.3 months of runway at that rate (XBRL company facts, accession 0001104659-26-126504).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [CARDAMYST (etripamil) topline data readout](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, met | "In October 2022, we announced positive and statistically significant topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil in patients with PSVT." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm)) |
| May 2024 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | scheduled | "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| May 2024 | [CARDAMYST (etripamil) NDA/BLA acceptance](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| September 6, 2024 | [JX02002 topline data readout](https://sec-api.dev/pdufa/jx02002) | MIST | PSVT in China | completed, positive | "On September 6, 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company announced positive topline data from the Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with PSVT in China." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837024015147/mist-20240930x10q.htm)) |
| November 12, 2024 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm)) |
| 1H 2025 | [CARDAMYST (etripamil) trial start](https://sec-api.dev/pdufa/etripamil) | MIST |  | scheduled | "Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in H1 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm)) |
| March 13, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218571_20250327.pdf%22)) |
| May 14, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925048160/tm2515019d1_ex99-1.htm)) |
| June 13, 2025 | [CARDAMYST (etripamil) NDA/BLA acceptance](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray, which was accepted." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| June 13, 2025 | [CARDAMYST (etripamil) NDA/BLA submission](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| July 11, 2025 | [CARDAMYST (etripamil) NDA/BLA acceptance](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On July 11, 2025, we announced that the FDA had accepted our response to the Complete Response Letter regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925067502/tm2520348-3_424b5.htm)) |
| July 11, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST | with paroxysmal supraventricular tachycardia | completed, complete response letter | "On July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| August 12, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm)) |
| November 12, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_ex99-1.htm)) |
| December 12, 2025 | [CARDAMYST (etripamil) FDA approval](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, approved | "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST® (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000110465926126504/mist-20260930x10q.htm)) |
| December 13, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, approved | "FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm)) |
| March 20, 2026 | [CARDAMYST (etripamil) earnings report](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_ex99-1.htm)) |
| May 13, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "13, 2026 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm)) |
| August 12, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "N.C., August 12, 2026 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the second quarter ended June 30, 2026, and provided corporate and regulatory updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_ex99-1.htm)) |
| November 13, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926126519/tm2629645d1_ex99-1.htm)) |
| 2H 2027 | [CARDAMYST (etripamil) trial start](https://sec-api.dev/pdufa/etripamil) | MIST |  | scheduled | "Company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm)) |
| 2H 2028 | [CARDAMYST (etripamil) topline data readout](https://sec-api.dev/pdufa/etripamil) | MIST |  | scheduled | "Ongoing Phase 3 pivotal trial (ReVeRA-301) evaluating etripamil nasal spray in atrial fibrillation with rapid ventricular rate (AFib-RVR) is on schedule; topline data expected in the second half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926126519/tm2629645d1_ex99-1.htm)) |

## Drugs

- [CARDAMYST (etripamil)](https://sec-api.dev/pdufa/etripamil): with paroxysmal supraventricular tachycardia
- [JX02002](https://sec-api.dev/pdufa/jx02002): psvt in china

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mist/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MIST catalysts: Milestone Pharmaceuticals Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mist/catalysts

```bibtex
@misc{secapidev_companies_mist_catalysts_20261116,
  title        = {MIST catalysts: Milestone Pharmaceuticals Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mist/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mist_catalysts_20261116","title":"MIST catalysts: Milestone Pharmaceuticals Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mist/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
